EP2797640B1 - Fibrous structure - Google Patents
Fibrous structure Download PDFInfo
- Publication number
- EP2797640B1 EP2797640B1 EP12823134.7A EP12823134A EP2797640B1 EP 2797640 B1 EP2797640 B1 EP 2797640B1 EP 12823134 A EP12823134 A EP 12823134A EP 2797640 B1 EP2797640 B1 EP 2797640B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- coating
- structure according
- blood
- fibers
- permeability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000463 material Substances 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 24
- 238000000576 coating method Methods 0.000 claims description 24
- 230000002792 vascular Effects 0.000 claims description 10
- 239000000835 fiber Substances 0.000 claims description 8
- 230000035699 permeability Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 206010020718 hyperplasia Diseases 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005465 channeling Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- -1 silver ions Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/42—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece
- D04H1/4326—Condensation or reaction polymers
- D04H1/4358—Polyurethanes
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/58—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H1/00—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres
- D04H1/40—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties
- D04H1/58—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives
- D04H1/64—Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties by applying, incorporating or activating chemical or thermoplastic bonding agents, e.g. adhesives the bonding agent being applied in wet state, e.g. chemical agents in dispersions or solutions
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/005—Synthetic yarns or filaments
- D04H3/009—Condensation or reaction polymers
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
- D04H3/07—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments otherwise than in a plane, e.g. in a tubular way
Definitions
- the invention relates to a structure with locally bonded fibers having a permeability to air between 0.5 ml / min * cm 2 and 1.5 ml / min * cm 2 .
- nonwovens are used as medical nonwovens and can be flat, curved, flexible or in particular also cylindrical. Depending on the embodiment, they are suitable for permanent use in the human body as an implant. This applies in particular to nonwovens made of biocompatible polyurethane, which can be used, for example, in a tubular shape as a vascular prosthesis. In this case, the nonwoven material can be used to form a tube wall, by which a channeling of blood for the reconstruction of degenerated blood vessels is possible.
- EP 2 083 750 A1 and the WO 2011 054 932 A1 which describe such nonwovens, is incorporated by reference.
- the material for the production of vascular prostheses must meet many requirements due to its properties, in order to be able to be used permanently for the formation of an artificial blood vessel. In addition to the sufficient mechanical and biological stability, this is above all the biological compatibility of the material, which is a basic prerequisite for the suitability for the production of an implantable medical device.
- a vascular prosthesis should provide reliable and permanent delivery of blood flow without leakage or occlusion of the prosthetic lumen during use.
- vascular prosthesis Apart from ruptures as the cause of leaks, it is essentially the material of the vascular prosthesis itself that can produce a leakage of blood.
- a woven textile as a prosthesis wall material is mentioned, which due to its porous structure does not have a reliable seal against blood loss.
- bleeding complications occur regularly, which is reduced after a long time by the onset of blood clotting and the resulting sealing of the pores.
- auxiliaries in the form of a sealing material are used for such materials in order to reduce the severe bleeding complications.
- Such material is used in the DE 600 03 046 T2 described.
- the structure used in the present invention has such a low porosity that bleeding through the prosthesis does not occur after the bloodstream has been opened.
- the permeability is chosen so that the blood cells entering the structure, and in particular a nonwoven, immediately clog the pores of the material.
- Closures of the prosthetic lumen are generally biological reactions to the foreign material. These occlusions are mainly caused by hyperplasia (excessive cell growth) on the anastomoses or thrombosis in the bloodstream.
- the structure used in this invention has, in particular as a nonwoven material, a similar compliance as a human artery.
- Thrombosis in the lumen of a vascular prosthesis is predominantly due to activation of the platelets on the foreign material.
- the material itself or its surface structure with the associated flow phenomena on the surface of the trigger of such activation is predominantly due to activation of the platelets on the foreign material.
- the medical fleece of the company Nonwotecc which is in the EP 2 083 750 A1 and the WO 2011 054 932 A1 described has structural Features of an extracellular matrix, so that can settle on the inner surface of a prosthesis made of this material endothelial cells and spread.
- the consequence of this cell growth is the formation of a luminal endothelial cell layer which completely obscures the underlying prosthetic material and thus significantly reduces coagulation activation in the blood.
- the base material used to make the web has very good biocompatible properties, which causes only minimal irritation of the platelets.
- the elastic properties of the structure and in particular of the nonwoven material are dimensioned such that the vascular prosthesis produced therefrom has a similar compliance to the natural arterial vessel.
- the object of the invention is to avoid undesired cell attachment to the structure and, when used as a vascular prosthesis, to increase the patency rate of the artificial vessel.
- a defined area of the material is subjected to a defined air pressure and then the air volume flow passing through the material is measured. This results in a special porosity, which can also be specified independently of the measurement method, for example, as an air resistance value.
- the fibers are made of polyurethane.
- the structure may comprise a nonwoven as it is for example in the WO 2008/049386 A1 is described.
- An advantageous embodiment provides that the fibers are glued to a cylinder and the coating is arranged on the cylinder inside. This coating smoothes protruding, possibly broken fibers, which can lead to an activation of the platelets in the passing blood (thrombus formation.) In addition, the penetration of growth factors from the surrounding wound area is reduced, thereby reducing the risk of hyperplasia in the anastomotic area.
- the coating of the inner surface of a vascular prosthesis made of a medical nonwoven surprisingly allows a further increase in the patency rate.
- the coating has gelatin, collagens and / or fibrin.
- gelatin can be absorbed after specific periods to be set in order to enable deposition of endothelial cells on the underlying fiber structure.
- a coating of gelatin, fibrin and / or collagen levels the microscopically rough surface of the nonwoven material, thereby reducing the flow-induced activation of the platelets. After a defined time, which can be set by the production of this coating, the coating is absorbed in the blood stream and gradually exposes the underlying nonwoven structure, on which now the endothelial cells can settle.
- the coating described here also reduces the risk of hyperplasia, since it leads to increased sealing the inside of the vessel comes to the outside, which prevents the influx of growth factors from the wound area surrounding the vessel. These growth factors obviously have a promoting effect on the development of hyperplasia in the lumen of the prosthesis.
- the suppression of hyperplasia can additionally be achieved by the incorporation of medicinal active substances into the coating, which are released in a time-controlled manner by the absorption of the coating. It is therefore proposed that the coating comprises a drug. To prevent inflammation, silver ions can be incorporated into the coating.
- the coating can be slowly absorbed in an implant, in particular an implanted artificial vessel. It is advantageous if it is absorbed after one to 30 days and preferably after 2 to 14 days to a maximum of 10% of the original amount.
- the measuring method is an in vivo model.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Description
Die Erfindung betrifft eine Struktur mit stellenweise miteinander verklebten Fasern, die eine Durchlässigkeit für Luft zwischen 0,5 ml/min*cm2 und 1,5 ml/min*cm2 aufweisen.The invention relates to a structure with locally bonded fibers having a permeability to air between 0.5 ml / min * cm 2 and 1.5 ml / min * cm 2 .
Derartige Vliese werden als medizinische Vliese eingesetzt und können plan, gebogen, flexibel oder insbesondere auch zylinderförmig sein. Je nach Ausführungsform sind sie dazu geeignet, als Implantat dauerhaft im menschlichen Körper eingesetzt zu werden. Dies trifft insbesondere auf Vliese aus biokompatiblem Polyurethan zu, die z.B. in röhrenförmiger Gestalt als Gefäßprothese eingesetzt werden können. In diesem Fall kann das Vliesmaterial dazu verwendet werden, eine Rohrwandung zu bilden, durch die eine Kanalisierung von Blut zur Rekonstruktion von degenerierten Blutgefäßen möglich wird. Auf die
Das Material zur Herstellung von Gefäßprothesen muss durch seine Eigenschaften viele Anforderungen erfüllen, um dauerhaft zur Bildung eines künstlichen Blutgefäßes verwendet werden zu können. Neben der ausreichenden mechanischen und biologischen Stabilität ist dies vor allem auch die biologische Verträglichkeit des Materials, welche eine Grundvorrausetzung für die Eignung zur Herstellung eines implantierbaren Medizinproduktes ist.The material for the production of vascular prostheses must meet many requirements due to its properties, in order to be able to be used permanently for the formation of an artificial blood vessel. In addition to the sufficient mechanical and biological stability, this is above all the biological compatibility of the material, which is a basic prerequisite for the suitability for the production of an implantable medical device.
Eine Gefäßprothese sollte eine zuverlässige und dauerhafte Bahnung des Blutstroms gewährleisten, ohne dass es im Laufe der Anwendung zu Undichtigkeiten oder Verschlüssen des Prothesenlumens kommt.A vascular prosthesis should provide reliable and permanent delivery of blood flow without leakage or occlusion of the prosthetic lumen during use.
Sieht man von Rupturen als Ursache von Undichtigkeiten ab, ist es im Wesentlichen das Material der Gefäßprothese selber, welches eine Leckage von Blut erzeugen kann. Beispielhaft sei hier die Verwendung eines gewebten Textils als Prothesenwandmaterial erwähnt, welches aufgrund seiner porösen Struktur keine zuverlässige Abdichtung gegen Blutverlust aufweist. Nach Implantation kommt es regelmäßig zu Blutungskomplikationen, die erst nach einer längeren Zeit durch Einsetzen der Blutgerinnung und der dadurch verursachten Abdichtung der Poren reduziert wird. Um diesen Prozess zu beschleunigen werden für solche Materialien Hilfsmittel in Form eines Dichtungsmaterials eingesetzt, um die starken Blutungskomplikationen zu reduzieren. Ein derartiges Material wird in der
Die in der vorliegenden Erfindung verwendete Struktur besitzt konstruktionsbedingt eine derart geringe Porosität, dass es nach Eröffnung der Blutbahn nicht zu einer Blutung durch die Prothese kommt. Die Durchlässigkeit ist so gewählt, dass die in die Struktur und insbesondere in ein Vlies eindringenden Blutzellen sofort die Poren des Materials verstopfen. Zudem kommt es zu einer Gerinnungsreaktion in dem Material, welche zusätzlich die Gefäßwandung abdichtet.By design, the structure used in the present invention has such a low porosity that bleeding through the prosthesis does not occur after the bloodstream has been opened. The permeability is chosen so that the blood cells entering the structure, and in particular a nonwoven, immediately clog the pores of the material. In addition, there is a coagulation reaction in the material, which additionally seals the vessel wall.
Verschlüsse des Prothesenlumens sind im Allgemeinen biologische Reaktionen auf das Fremdmaterial. Diese Verschlüsse werden im Wesentlichen verursacht durch Hyperplasie (überschießendes Zellwachstum) an den Anastomosen oder einer Thrombose in der Blutbahn.Closures of the prosthetic lumen are generally biological reactions to the foreign material. These occlusions are mainly caused by hyperplasia (excessive cell growth) on the anastomoses or thrombosis in the bloodstream.
In der Wissenschaft wird als Hauptursache für das Auftreten einer Hyperplasie an den Anastomosen ein Compliance-Mismatch genannt. Dieses Merkmal tritt dann in Erscheinung, wenn sich die Dehneigenschaften des Prothesenmaterials signifikant von denen des nativen Gefäßes unterscheiden. Die bei dieser Erfindung verwendete Struktur besitzt insbesondere als Vliesmaterial eine ähnliche Compliance wie eine menschliche Arterie.In science, the main cause of the occurrence of hyperplasia in the anastomoses is called a compliance mismatch. This feature occurs when the stretch characteristics of the prosthetic material differ significantly from those of the native vessel. The structure used in this invention has, in particular as a nonwoven material, a similar compliance as a human artery.
Eine Thrombose im Lumen einer Gefäßprothese entsteht überwiegend aufgrund einer Aktivierung der Thrombozyten an dem Fremdmaterial. Dabei können das Material selber oder seine Oberflächenstruktur mit den damit verbundenen Strömungsphänomenen an der Oberfläche der Auslöser einer solchen Aktivierung sein.Thrombosis in the lumen of a vascular prosthesis is predominantly due to activation of the platelets on the foreign material. In this case, the material itself or its surface structure with the associated flow phenomena on the surface of the trigger of such activation.
Ziel der Bereitstellung eines optimalen Materials für eine Gefäßprothese oder eine flächige Abdichtung eines Blutraumes ist es also, dass das Material den Blutzellen gegenüber nicht als störendes Fremdmaterial erscheint. Dazu werden verschiedene technologische Ansätze verfolgt.The aim of providing an optimal material for a vascular prosthesis or a surface seal of a blood space, it is therefore that the material does not appear to the blood cells as a disturbing foreign material. For this purpose, various technological approaches are pursued.
Das medizinische Vlies der Firma Nonwotecc, das in der
Das zur Herstellung des Vlieses verwendete Grundmaterial besitzt sehr gute biokompatible Eigenschaften, welche nur eine minimale Reizung der Thrombozyten hervorruft.The base material used to make the web has very good biocompatible properties, which causes only minimal irritation of the platelets.
Letztlich sind die elastischen Eigenschaften der Struktur und insbesondere des Vliesmaterials derart dimensioniert, dass die daraus hergestellte Gefäßprothese eine dem natürlichen arteriellen Gefäß ähnliche Compliance aufweist.Ultimately, the elastic properties of the structure and in particular of the nonwoven material are dimensioned such that the vascular prosthesis produced therefrom has a similar compliance to the natural arterial vessel.
Ausgehend hiervon liegt der Erfindung die Aufgabe zu Grunde, eine unerwünschte Zellanlagerung an der Struktur zu vermeiden und bei der Verwendung als Gefäßprothese die Offenheitsrate des künstlichen Gefäßes zu erhöhen.Proceeding from this, the object of the invention is to avoid undesired cell attachment to the structure and, when used as a vascular prosthesis, to increase the patency rate of the artificial vessel.
Dies wird durch eine mindestens einseitige Beschichtung erzielt, die die Durchlässigkeit der Struktur auf unter 0,2 ml/min*cm2 reduziert.This is achieved by an at least one sided coating which reduces the permeability of the structure to less than 0.2 ml / min * cm 2 .
Somit wird eine relativ dichte Membran beschichtet, obwohl zur Erhöhung der Dichtheit eine Beschichtung nicht mehr notwendig wäre und eine poröse Oberfläche gut für das Zellwachstum wäre.Thus, a relatively dense membrane is coated, although to increase tightness, a coating would no longer be necessary and a porous surface would be good for cell growth.
Zur Bestimmung der Permeabilität/Porosität des Vlieses wird eine definierte Fläche des Materials mit einem definierten Luftdruck beaufschlagt und anschließend der durch das Material strömende Luftvolumenstrom gemessen. Dadurch ergibt sich eine spezielle Porosität, die auch unabhängig von der Meßmethode beispielsweise als Luftwiderstandswert angegeben werden kann.To determine the permeability / porosity of the nonwoven, a defined area of the material is subjected to a defined air pressure and then the air volume flow passing through the material is measured. This results in a special porosity, which can also be specified independently of the measurement method, for example, as an air resistance value.
Vorteilhaft ist es, wenn die Fasern aus Polyurethan bestehen.It is advantageous if the fibers are made of polyurethane.
Insbesondere zur Herstellung künstlicher Gefäße kann die Struktur ein Vlies aufweisen wie es beispielsweise in der
Eine vorteilhafte Ausführungsvariante sieht vor, dass die Fasern zu einem Zylinder verklebt sind und die Beschichtung an der Zylinderinnenseite angeordnet ist. Diese Beschichtung glättet abstehende, ggf. gebrochene Fasern, die zu einer Aktivierung der Thrombozyten im vorbeiströmenden Blut führen können (Thrombenbildung.) Außerdem wird das Eindringen von Wachstumsfaktoren aus dem umliegenden Wundbereich vermindert, um dadurch die Gefahr einer Hyperplasie im Anastomosenbereich zu reduzieren.An advantageous embodiment provides that the fibers are glued to a cylinder and the coating is arranged on the cylinder inside. This coating smoothes protruding, possibly broken fibers, which can lead to an activation of the platelets in the passing blood (thrombus formation.) In addition, the penetration of growth factors from the surrounding wound area is reduced, thereby reducing the risk of hyperplasia in the anastomotic area.
Die Beschichtung der Innenoberfläche einer Gefäßprothese aus einem medizinischen Vlies ermöglicht überaschenderweise eine weitere Erhöhung der Offenheitsrate.The coating of the inner surface of a vascular prosthesis made of a medical nonwoven surprisingly allows a further increase in the patency rate.
Erste Untersuchungen lassen vermuten, dass die Wahrscheinlichkeit einer dauerhaften Offenheit der Prothese dann am größten ist, wenn es zunächst nach dem initialen Blutkontakt mit der Protheseninnenoberfläche zu einer möglichst geringen Fremdkörperreaktion kommt. Nach dieser ersten Kontaktzeit sollte eine dauerhafte autologe Beschichtung der Materialoberfläche von statten gehen, die die Innenoberfläche der Prothese möglichst als körpereigenes Gewebe darstellen lässt. Eine solche autologe Beschichtung besteht im optimalen Fall aus einer geschlossenen Endothelzellschicht.Preliminary investigations suggest that the likelihood of a permanent openness of the prosthesis is greatest when it first comes to the least possible foreign body reaction after the initial blood contact with the prosthetic inner surface. After this first contact time, a permanent autologous coating of the material surface should be provided which, if possible, makes the inner surface of the prosthesis represent the body's own tissue. Such an autologous coating consists in the optimal case of a closed endothelial cell layer.
Vorteilhaft ist es, wenn die Beschichtung Gelatine, Kollagene und/oder Fibrin aufweist. Insbesondere Gelatine kann nach gezielt einzustellenden Zeiträumen resorbiert werden, um eine Anlagerung von Endothelzellen auf der darunterliegenden Faserstruktur ermöglichen zu können.It is advantageous if the coating has gelatin, collagens and / or fibrin. In particular, gelatin can be absorbed after specific periods to be set in order to enable deposition of endothelial cells on the underlying fiber structure.
Eine Beschichtung aus Gelatine, Fibrin und/oder Kollagen ebnet die mikroskopisch raue Oberfläche des Vliesmaterials und reduziert damit die strömungsbedingte Aktivierung der Thrombozyten. Nach einer definierten Zeit, die durch die Herstellung dieser Beschichtung eingestellt werden kann, wird die Beschichtung im Blutstrom resorbiert und legt nach und nach die darunterliegende Vliesstruktur frei, auf die sich nun die Endothelzellen ansiedeln können.A coating of gelatin, fibrin and / or collagen levels the microscopically rough surface of the nonwoven material, thereby reducing the flow-induced activation of the platelets. After a defined time, which can be set by the production of this coating, the coating is absorbed in the blood stream and gradually exposes the underlying nonwoven structure, on which now the endothelial cells can settle.
Außerdem wird durch eine hier beschriebene Beschichtung auch das Risiko einer Hyperplasie reduziert, da es zu einer verstärkten Abdichtung der Gefäßinnenseite nach außen kommt, die das Einströmen von Wachstumsfaktoren aus dem das Gefäß umgebenden Wundgebiet verhindert. Diese Wachstumsfaktoren haben offensichtlich einen fördernden Effekt auf die Entstehung einer Hyperplasie im Lumen der Prothese.In addition, the coating described here also reduces the risk of hyperplasia, since it leads to increased sealing the inside of the vessel comes to the outside, which prevents the influx of growth factors from the wound area surrounding the vessel. These growth factors obviously have a promoting effect on the development of hyperplasia in the lumen of the prosthesis.
Die Unterdrückung einer Hyperplasie kann zusätzlich durch das Einbinden von arzneilichen Wirkstoffen in die Beschichtung erreicht werden, die zeitgesteuert durch die Resorption der Beschichtung freigesetzt werden. Es wird daher vorgeschlagen, dass die Beschichtung ein Medikament aufweist. Zur Vorbeugung gegen eine Entzündung können Silberionen in die Beschichtung eingebunden werden.The suppression of hyperplasia can additionally be achieved by the incorporation of medicinal active substances into the coating, which are released in a time-controlled manner by the absorption of the coating. It is therefore proposed that the coating comprises a drug. To prevent inflammation, silver ions can be incorporated into the coating.
Die Beschichtung kann bei einem Implantat wie insbesondere einem implantierten künstlichen Gefäß langsam absorbiert werden. Vorteilhaft ist es, wenn sie nach ein bis 30 Tagen und vorzugsweise nach 2 bis 14 Tagen auf maximal 10 % der ursprünglichen Menge resorbiert wird. Als Meßmethode eignet sich ein in vivo Modell.The coating can be slowly absorbed in an implant, in particular an implanted artificial vessel. It is advantageous if it is absorbed after one to 30 days and preferably after 2 to 14 days to a maximum of 10% of the original amount. The measuring method is an in vivo model.
Claims (8)
- Structure for manufacturing vascular prostheses, having fibers that are adhesively bonded in certain places and that have a permeability for air between 0.5 ml/min*cm2 and 1.5 ml/min*cm2, wherein the structure comprises a non-woven material and the non-woven material has biocompatible properties,
characterized in that it has at least a single-sided coating, which reduces the permeability of the structure to below 0.2 ml/min*cm2. - Structure according to claim 1, characterized in that the fibers are made of polyurethane.
- Structure according to one of the preceding claims, characterized in that the fibers are adhesively bonded to form a cylinder and the coating is arranged at the inner surface of the cylinder.
- Structure according to one of the preceding claims, characterized in that the coating comprises gelatine.
- Structure according to one of the preceding claims, characterized in that the coating comprises collagens.
- Structure according to one of the preceding claims, characterized in that the coating comprises fibrin.
- Structure according to one of the preceding claims, characterized in that the coating comprises a medicament.
- Structure according to one of the preceding claims, characterized in that the coating is reabsorbed after one to 30 days and preferably after 2 to 14 days up to maximally 10% of the original amount.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011122490 | 2011-12-29 | ||
DE102012008656A DE102012008656A1 (en) | 2011-12-29 | 2012-05-03 | Structure with fibers glued together in places |
PCT/DE2012/001211 WO2013097841A1 (en) | 2011-12-29 | 2012-12-19 | Structure having fibres which are adhesively bonded to one another in locations |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2797640A1 EP2797640A1 (en) | 2014-11-05 |
EP2797640B1 true EP2797640B1 (en) | 2016-07-20 |
EP2797640B8 EP2797640B8 (en) | 2016-09-21 |
Family
ID=48607967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12823134.7A Active EP2797640B8 (en) | 2011-12-29 | 2012-12-19 | Fibrous structure |
Country Status (7)
Country | Link |
---|---|
US (1) | US9345808B2 (en) |
EP (1) | EP2797640B8 (en) |
JP (1) | JP6804824B2 (en) |
CN (1) | CN104039364B (en) |
CA (1) | CA2860347A1 (en) |
DE (1) | DE102012008656A1 (en) |
WO (1) | WO2013097841A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10939990B2 (en) * | 2017-11-28 | 2021-03-09 | Medtronic Vascular, Inc. | Graft material having selectively advanced permeability structure and method |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3608158A1 (en) * | 1986-03-12 | 1987-09-17 | Braun Melsungen Ag | VESSELED PROSTHESIS IMPREGNATED WITH CROSSLINED GELATINE AND METHOD FOR THE PRODUCTION THEREOF |
DE3913926A1 (en) * | 1989-04-27 | 1990-10-31 | Heinz Helmut Dr Med Werner | Vascular prosthesis, esp. of PET with resorbable plastic coatings - esp. of poly:lactide, applied as soln. then treatment with non-solvent |
US5851229A (en) * | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
US7241309B2 (en) * | 1999-04-15 | 2007-07-10 | Scimed Life Systems, Inc. | Self-aggregating protein compositions and use as sealants |
JPH11164881A (en) * | 1997-09-17 | 1999-06-22 | Naisemu:Kk | Medical material and manufacture thereof |
GB9920732D0 (en) | 1999-09-03 | 1999-11-03 | Sulzer Vascutek Ltd | Sealant |
US20020084178A1 (en) | 2000-12-19 | 2002-07-04 | Nicast Corporation Ltd. | Method and apparatus for manufacturing polymer fiber shells via electrospinning |
DE10125712B4 (en) * | 2001-05-21 | 2012-06-06 | Aesculap Ag | Implant for surgery |
US8101196B2 (en) * | 2001-06-26 | 2012-01-24 | Biointeractions, Ltd. | Polysaccharide biomaterials and methods of use thereof |
US7871946B2 (en) * | 2003-10-09 | 2011-01-18 | Kuraray Co., Ltd. | Nonwoven fabric composed of ultra-fine continuous fibers, and production process and application thereof |
JP2008505713A (en) * | 2004-07-07 | 2008-02-28 | クック・インコーポレイテッド | Graft, stent graft, and manufacturing method |
DE102006051013A1 (en) | 2006-05-02 | 2007-11-08 | Nonwotecc Medical Gmbh | Surface structure for use as stent or fiber patch, has fibers adhered with one another and broken by ultrasonic treatment using ultrasonic generator, and stent drawn over arbor, where surface of arbor possesses small surface roughness |
DE102006050129B3 (en) | 2006-10-25 | 2008-01-31 | Krauss-Maffei Wegmann Gmbh & Co. Kg | Chain slack measuring method for use in tracked vehicle, involves fixing three extension elements at upper trough of chain such that two extension elements are arranged at length section, and third extension element is arranged on center |
DE102007047246A1 (en) | 2007-09-26 | 2009-04-02 | Aesculap Ag | Reinforced vascular prosthesis with antimicrobial long-term effect |
US20100119578A1 (en) * | 2008-11-07 | 2010-05-13 | Specialized Vascular Technologies, Inc. | Extracellular matrix modulating coatings for medical devices |
DE102009037134A1 (en) | 2009-07-31 | 2011-02-03 | Aesculap Ag | Tubular implant for replacement of natural blood vessels |
WO2011054932A1 (en) | 2009-11-05 | 2011-05-12 | Nonwotecc Medical Gmbh | Non-woven fabric for medical use and process for the preparation thereof |
-
2012
- 2012-05-03 DE DE102012008656A patent/DE102012008656A1/en not_active Withdrawn
- 2012-12-19 EP EP12823134.7A patent/EP2797640B8/en active Active
- 2012-12-19 CN CN201280064232.2A patent/CN104039364B/en active Active
- 2012-12-19 JP JP2014549359A patent/JP6804824B2/en active Active
- 2012-12-19 CA CA2860347A patent/CA2860347A1/en not_active Abandoned
- 2012-12-19 WO PCT/DE2012/001211 patent/WO2013097841A1/en active Application Filing
- 2012-12-19 US US14/369,667 patent/US9345808B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DE102012008656A1 (en) | 2013-07-04 |
CN104039364A (en) | 2014-09-10 |
JP2015503373A (en) | 2015-02-02 |
EP2797640B8 (en) | 2016-09-21 |
CA2860347A1 (en) | 2013-07-04 |
US20140364937A1 (en) | 2014-12-11 |
CN104039364B (en) | 2017-03-01 |
US9345808B2 (en) | 2016-05-24 |
EP2797640A1 (en) | 2014-11-05 |
JP6804824B2 (en) | 2020-12-23 |
WO2013097841A1 (en) | 2013-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0248246B1 (en) | Vascular graft wall | |
EP0248247B1 (en) | Vascular graft wall | |
DE2508570C2 (en) | Vascular prosthesis made of expanded and porous polytetrafluoroethylene | |
DE69232899T2 (en) | Implantable multi-lumen, extruded device with controlled porosity and method of manufacture | |
DE69524501T2 (en) | Vascular graft impregnated with a heparin-containing collagen sealant | |
DE69728216T2 (en) | Endovascular implant with controlled porosity | |
DE69938264T2 (en) | Process for the preparation of porous, synthetic vascular grafts with oriented wax channels | |
DE69938295T2 (en) | SMALL-LIQUID BIOLOGICAL TRANSPLANT WITH THERAPEUTIC ADMINISTRATION DEVICE | |
EP1579827A2 (en) | Cardiovascular implant and method and device for manufacturing thereof | |
DE69631448T2 (en) | Bypass vein graft | |
CN105744912A (en) | Artificial vascular graft | |
EP1389075B1 (en) | Surgical implant and method for the production | |
EP2797640B1 (en) | Fibrous structure | |
DE102019121562B4 (en) | Medical device for treating aneurysms | |
DE102009037134A1 (en) | Tubular implant for replacement of natural blood vessels | |
DE69007999T2 (en) | Prosthesis for a living organ. | |
DE60017899T2 (en) | TISSUE TRANSPLANT FROM EXPANDED POLYTETRAFLUOROETHYLENE WITH INCREASED HEALING | |
WO2000071052A1 (en) | Highly flexible coating for stents and/or stent grafts and/or vascular stent prostheses | |
EP1905464B1 (en) | Implant and method for its production | |
AT404794B (en) | Cardiovascular prosthesis | |
EP4045097A1 (en) | Sealant material for a medical implant | |
EP2515960B1 (en) | Implant, method for producing such an implant, and use | |
DE102011000400A1 (en) | Conduit-valve prosthesis e.g. conduit-cardiac valve prosthesis, for e.g. replacing deflective aorta valve for patient, has cusps formed at bulb-like projections of body, where prosthesis is integrally formed based on polyurethane-material | |
EP0941739A1 (en) | Porous coated artificial implant material and corresponding preparation process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140729 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160211 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: LANGUAGE OF EP DOCUMENT: GERMAN |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 813511 Country of ref document: AT Kind code of ref document: T Effective date: 20160815 |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: OCCLUTECH HOLDING AG |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 502012007739 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161021 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161121 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 502012007739 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161020 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
26N | No opposition filed |
Effective date: 20170421 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161219 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161231 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170102 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20161231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20121219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160720 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 813511 Country of ref document: AT Kind code of ref document: T Effective date: 20171219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171219 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230527 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20230629 AND 20230705 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 502012007739 Country of ref document: DE Owner name: OCCLUTECH GMBH, DE Free format text: FORMER OWNER: OCCLUTECH HOLDING AG, SCHAFFHAUSEN, CH |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20231113 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20231113 Year of fee payment: 12 Ref country code: DE Payment date: 20231221 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20231221 Year of fee payment: 12 |